GRACELL BIOTECHNOLOGIES INC. reports a Return on Equity (ROE) of -30.66%.

What is GRCL's dividend yield?

GRACELL BIOTECHNOLOGIES INC. offers a dividend yield of 0.00%.

What is GRCL's Deepscope Quality Score?

Deepscope rates GRCL's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GRCL?

Deepscope's AI Timing Score for GRCL is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GRCL belong to?

GRACELL BIOTECHNOLOGIES INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu GRCL (NASDAQ) | GRACELL BIOTECHNOLOGIES INC.

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2023-09-30)

GRCL

GRACELL BIOTECHNOLOGIES INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 84

USD 519.90

14.40 (2.85%) Day Change

Watchlist Portfolio Compare Chart

0.07

D/E

-30.7%

ROE

-26.3%

ROA

0.00%

Div Yield

GRACELL BIOTECHNOLOGIES INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 519.90 Price 14.40 (2.85%) Day Change	NEWS SCORE: 84

GRCL Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Không tốt , ...

Yếu tố Chất lượng

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	84
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	519.90
PBV / Sector	0.61 / 4.63 GREAT
Earning Per Share	-261.03

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	3.21 M GREAT
Average 1W Daily Value	1.05 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 449.48
NPM Average (%) / Sector	-127,289.62 / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-26.30 / 30.58
ROA Average (%) / Sector	-36.38 / -347.17
ROA Change Average (%) / Sector	-12.15 / 5,125.52
ROE (%) / Sector	-30.66 / -3.58
ROE Average (%) / Sector	-46.81 / 40.65
ROE Change Average (%) / Sector	-18.59 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Chi tiết đăng ký

Analyze Date	2026-06-06 09:08:45
Symbol	GRCL
Name	GRACELL BIOTECHNOLOGIES INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	96.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	989.87 / 8,857.28

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Building 12, Block B, Suzhou, China, 215123

Phone: 86 512 6262 6701

Website: https://www.gracellbio.com

Employees: 314

Sector: Healthcare >> Biotechnology

Description: Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.